Funding
← Back to your selection

Pfizer Ventures

Activity from announced rounds

Activity in this selectionJan 31, 2026 · Jan 1, 2026

Pfizer Ventures is the venture unit whose official portfolio includes TRIMTECH and TwoStep and whose partner Rana Al-Hallaq is identified in company materials.

Recorded funding activity

TwoStep develops targeted cancer therapies. TRIMTECH develops protein-degrading medicines for neurological disease, while Crossbow develops cancer antibodies. These relationships remain distinct from generic Pfizer corporate participation.

Sources
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$135.2M
3 disclosed · full round size, not this investor’s share

By stage

Seed1
Series A1
Undisclosed1

By primary sector

Biotech3

By country

China1
France1
United States1

Rounds

3 in this selection
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed
Enodia Therapeutics

Develops small-molecule therapies for targeted protein degradation at the point of synthesis

Role not disclosed